SNOT-22 and Nasal Blockage Score (NBS)
Benralizumab treated subjects showed significant improvement in both the SNOT-22 clinical survey and nasal blockage score by week 20 (SD=20.8; P=0.001, and SD=1.2, P=0.038 respectively) compared to baseline screening (week 0). All patients treated with benralizumab had an improved SNOT-22 score with a mean decrease of -19.2 points (-33% decrease from baseline). More than half the benralizumab treated patients had an improved nasal blockage score (NBS) 7/12 (P=0.038).
There was also an improvement in the SNOT-22 score among placebo treated patients (SD=20.1; P=0.024) although the mean decrease of -14.6 points (-22%) was less than that seen in the benralizumab treated group. Placebo treated patients had no significant improvement in the nasal blockage score (P=0.399). Within the first month of treatment, the SNOT-22 scores in the placebo and benralizumab treatment groups overlapped. From that point on (week 4 to follow-up week 24), the benralizumab group continued to improve (mean change -13.1 points; P=0.077) but the placebo group had minimal change (mean decrease -1.2 points; P=0.851) as shown in Figure 4.